Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec;24(6):978-988.
doi: 10.1007/s11102-021-01188-7. Epub 2021 Sep 27.

Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis

Karan J Yagnik  1 , Dana Erickson  2 , Irina Bancos  2 , John L D Atkinson  1 , Garret Choby  3 , Maria Peris-Celda  1 , Jamie J Van Gompel  4   5
Affiliations
Meta-Analysis

Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis

Karan J Yagnik et al. Pituitary. 2021 Dec.

Abstract

Purpose: In Prolactinomas, surgery or radiation are reserved for DA failure due to tumor resistance, intolerance to medication-induced side-effects, or patient preference. This systematic review and meta-analysis summarizes the currently available literature regarding the effectiveness of surgery to treat prolactinomas in patients who have failed DA therapy.

Method: A literature search was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for studies that reported outcomes of medically resistant and intolerant prolactinoma treated surgically.

Results: 10 articles (Total N = 816, Surgery N = 657) met the inclusion criteria. 38% of patients who underwent surgery following DA failure achieved remission without need for further treatment (p < 0.001, I2 = 67.09%) with a median follow-up of 49.2 +/- 40 months. 62% achieved remission with multimodal treatment (p < 0.001, I2 = 93.28%) with a median follow-up of 53 +/- 39.8 months. 16% of cases demonstrated recurrence after early remission (p = 0.02, I2 = 62.91%) with recurrence occurring on average at 27 +/- 9 months. Overall, 46% of patients required reinstitution of postoperative DA therapy at last follow up (p < 0.001, I2 = 82.57%). Subgroup analysis of macroprolactinoma and microprolactinoma has demonstrated that there is no statistical significance in achieving long-term remission with surgery stand-alone in macroprolactinoma group (p = 0.49) although 43% of patients were able to achieve remission with multimodal therapy at last follow-up in the same group (p < 0.001, I2 = 86.34%).

Conclusions: This systematic review and meta-analysis revealed 38% of operated patients achieved remission, while 62% achieved remission when additional modes of therapy were implemented. Therefore, although surgery has not been initial therapeutic choice for prolactinoma, it plays a significant role in medically failed prolactinoma care.

Keywords: Cabergoline resistant; Dopamine Agonist (DA) resistant; Dopamine Agonist intolerant; Medically Failed Prolactinoma; Prolactinoma.

PubMed Disclaimer

References

    1. Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20–27. https://doi.org/10.1159/000497746 - DOI - PubMed
    1. Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3–6. doi: https://doi.org/10.1007/s11102-005-5079-0 - DOI - PubMed
    1. Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692 - DOI - PubMed
    1. Ono M, Miki N, Kawamata T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721–4727. doi: https://doi.org/10.1210/jc.2007-2758 - DOI - PubMed
    1. Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228–238. https://doi.org/10.2165/00002018-199614040-00003 - DOI - PubMed

LinkOut - more resources